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Purpose: CADASIL is a small-vessel disease caused by a cysteine-
altering pathogenic variant in one of the 34 epidermal growth
factor-like repeat (EGFr) domains of the NOTCH3 protein. We
recently found that pathogenic variant in EGFr domains 7–34 have
an unexpectedly high frequency in the general population (1:300).
We hypothesized that EGFr 7–34 pathogenic variant more
frequently cause a much milder phenotype, thereby explaining an
important part of CADASIL disease variability.
Methods: Age at first stroke, survival and white matter hyper-
intensity volume were compared between 664 CADASIL patients
with either a NOTCH3 EGFr 1–6 pathogenic variant or an EGFr 7–34
pathogenic variant. The frequencies of NOTCH3 EGFr 1–6 and EGFr
7–34 pathogenic variant were compared between individuals in the
genome Aggregation Database and CADASIL patients.
Results: CADASIL patients with an EGFr 1–6 pathogenic variant
have a 12-year earlier onset of stroke than those with an EGFr 7–34
pathogenic variant, lower survival, and higher white matter
hyperintensity volumes. Among diagnosed CADASIL patients, 70%
have an EGFr 1–6 pathogenic variant, whereas EGFr 7–34 pathogenic
variant strongly predominate in the population.
Conclusion: NOTCH3 pathogenic variant position is the most
important determinant of CADASIL disease severity, with EGFr 7–34
pathogenic variant predisposing to a later onset of stroke and longer
survival.
Genetics in Medicine (2019) 21:676–682; https://doi.org/10.1038/s41436-
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INTRODUCTION
CADASIL (cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy) is the most
prevalent hereditary cerebral small-vessel disease, caused by
highly distinctive cysteine-altering missense pathogenic var-
iant (PV) in the NOTCH3 gene.1,2 More than 200 of such
distinct NOTCH3 PV have been described in CADASIL
families worldwide.3 Recently, we have shown that these PV
occur in 1:300 individuals in the general population world-
wide, which is 100-fold higher than the minimal estimated
CADASIL prevalence.4 This unexpectedly high frequency
not only supports the hypothesis that CADASIL is under-
diagnosed, but also strongly suggests that, in the general
population, these PV are probably associated with a much
milder small-vessel disease phenotype, or may sometimes
even be non-penetrant.
Although NOTCH3 PV in the population are identical to
those found in CADASIL patients, we previously found that
the PV in the general population are predominantly located in
epidermal growth factor-like repeat (EGFr) domains 7–34 of
the NOTCH3 protein, whereas PV in CADASIL patients are
predominantly located in EGFr domains 1–6. This suggests
that EGFr domain 1–6 PV are associated with a more severe
or ‘classical’ CADASIL phenotype, whereas EGFr 7–34 PV are
generally milder. Indeed, in a small CADASIL cohort we
previously showed that EGFr domain 1-6 PV are associated
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with a higher brain lesion load on magnetic resonance
imaging (MRI), than EGFr domain 7–34 PV.4 As such, the
NOTCH3 PV position may be an important, hitherto
unrecognized, factor underlying CADASIL disease variabil-
ity—possibly much more so than the previously identified
vascular risk factors and genetic modifiers, which account for
only a small part of the disease variability.5-8 Classically,
CADASIL patients have their first stroke at age 45–50 years9
and develop progressive cognitive impairment leading to
vascular dementia. Life expectancy is reduced, and has been
estimated at 64.6 years for males and 70.7 years for females.10
Other frequent symptoms are migraine with aura, mood
disturbances and apathy.11 Typical brain MRI abnormalities
are progressive symmetrical white matter hyperintensities
(WMHs), lacunes, microbleeds and brain atrophy.12–14
Disease variability is increasingly recognized, especially at
the milder end, with patients with a much later disease onset
well into the eighth decade.4,15,16
In the current study, we aimed to validate and further
delineate the effect of NOTCH3 PV position on CADASIL
disease variability, by analysing the correlation between PV
position and brain MRI lesion load, age at first stroke and
survival in two independent large CADASIL samples.4
Furthermore, we compared the locations of NOTCH3 PV in
European CADASIL patients with those in the general
European population, using the genome Aggregation Database
(gnomAD).
MATERIALS AND METHODS
Analysis of disease severity and survival in 251 Dutch
CADASIL patients
The files of 251 patients in the Dutch CADASIL registry who
visited the Leiden University Medical Center between 1998 and
2017 were evaluated. In all patients, CADASIL had been
confirmed by the detection of an EGFr domain cysteine-altering
NOTCH3 PV. Individuals had either had diagnostic DNA
testing after a clinical diagnosis, or had requested predictive
genetic testing due to a positive family history for CADASIL.
Only individuals with a heterozygous PV were included in the
study. A patient with a compound heterozygous PV and
a patient with a homozygous PV were therefore excluded.
Patients originated from 131 unrelated families, with 45
distinct PV in 16 discrete EGFr domains. Of these patients,
153 had a PV in one of EGFr domains 1–6 and 98 had a PV in
one of EGFr domains 7–34. Medical records were examined by
an investigator blinded to the location of the PV, who recorded
the date of birth, sex and family structure, occurrence and age
at onset of first stroke, and presence or absence of migraine
with aura, as well as cardiovascular risk factors including history
of smoking, hypertension (systolic (>140mmHg) or diastolic
(>90mmHg), or antihypertensive treatment), and previous
diagnosis of diabetes mellitus. Stroke was defined as an episode
of acute neurological deficits lasting longer than 24 h. If a brain
MRI scan was available, stroke was verified. Migraine with aura
was defined as an episode of typical visual aura, or visual aura
followed or accompanied by spreading sensory disturbances
(tingling or numbness) in a limb or verbal dysphasia, lasting
between 10 and 30min, followed (or not) by migraine
headache. If events were difficult to classify, they were
independently assessed by two experienced physicians and
classified by consensus. Hypercholesterolaemia could not be
assessed accurately from the patient records because, according
to international guidelines,17 cholesterol-lowering agents are
prescribed to all patients who have had a stroke as a
preventative measure. This was therefore not included in the
analysis. Survival data were obtained from the Dutch population
registry. The study was approved by the Medical Ethics
Committee of the Leiden University Medical Center (G17.073).
Analysis of brain MRI WMH volume in 412 European
CADASIL patients
The European CADASIL sample included 470 CADASIL
patients, recruited from 5 European countries (France,
Germany, United Kingdom, Italy and the Netherlands), in
whom brain MRI WMH volumes had been previously
quantified.7 Data on the age at first stroke and survival were
not available for this sample. We excluded from the analysis the
51 patients from the Netherlands, as this was the discovery
sample of the genotype–phenotype correlation described in a
previous study.4 We also excluded six patients who did not have
a missense PV,18,19 and one patient whose age was not known.
A total of 412 patients were included in the final analysis. In this
sample, there were 97 distinct PV in 21 discrete EGFr domains.
Of the 412 patients, 290 had a PV in one of EGFr domains 1–6
and 122 had a PV in one of EGFr domains 7–34. For all
patients, date of birth, sex, country of origin, brain MRI WMH
volume, APOE carrier status, and cardiovascular risk factors
including smoking status, number of pack years (multiplication
of number of cigarette packs smoked per day with number of
years of smoking), hypertension, hypercholesterolaemia and
diabetes mellitus, were registered in a database. APOE carrier
status was grouped based on the presence of the ϵ2 and ϵ4
allele.8 For 35 individuals, the APOE genotype was not known.
These individuals were coded as a separate group. Details on
brain MRI processing and quantification have been described
previously.7 Briefly, brain MRI scans were performed at each
site, at field strengths between 0.5 and 3 Tesla. WMH volumes
were measured on fluid attenuated inversion recovery (FLAIR)
sequences using a semi-automated method, where all hyper-
intense subcortical lesions on FLAIR imaging were labelled
WMH. The intracranial cavity was assessed using an automated
three-dimensional image-segmentation algorithm followed by
manual correction. WMH volumes were divided by the
intracranial cavity volume to normalize for head size. Given
the left-skewed distribution of the WMH volume, the square
root was taken to obtain a normal distribution. This is referred
to as the normalized WMH volume (nWMHV).
Analysis of NOTCH3 PV in the general population using
gnomAD
We previously found an unexpectedly high frequency of EGFr
cysteine-altering NOTCH3 PV in a large exome database, the
RUTTEN et al ARTICLE
12
34
56
78
9
0(
):,
;
GENETICS in MEDICINE | Volume 21 | Number 3 | March 2019 677
Exome Aggregation Consortium (ExAC).20 This database has
now been expanded and renamed gnomAD (http://gnomad.
broadinstitute.org/). GnomAD includes more than double the
number of individuals in ExAC, with 123,136 exome
sequences and 15,496 whole-genome sequences from unre-
lated individuals sequenced as part of various disease-specific
and population genetic studies.20 We queried gnomAD for
archetypal CADASIL-causing PV; i.e., missense PV leading to
the gain or loss of a cysteine residue in one of the 34 EGFr
domains of the NOTCH3 protein (amino acid residues
40–1373) (http://www.uniprot.org). To compare the PV
location of individuals in gnomAD with the PV location
found in diagnosed CADASIL patients, we selected only those
individuals of European descent (76,266 individuals), and
compared these with 463 diagnosed European CADASIL
patients.7 For PV annotation, the reference sequence
NM_000435.2 was used, and sequence variants were
described according to the Human Genome Variation Society
nomenclature recommendations.
Statistical analysis
Differences in baseline characteristics (age, sex and cardio-
vascular risk factors) were analysed using independent-sample
t-tests for continuous variables and Chi-squared tests for
categorical variables. Differences between the prevalence of
stroke and migraine with aura in patients with a PV in EGFr
domains 1–6 versus patients with a PV in EGFr domains 7–34
were analysed using Chi-squared tests. Differences in the age
of onset of first stroke and survival were analysed through
time-to-event analyses and log-rank tests, as this also
incorporates data from individuals who had not yet had an
event (stroke or death) at the time of the last follow-up (right
censoring). Correction for age, sex and cardiovascular
risk factors was performed using Cox-regression analysis.
To account for a possible effect caused by multiple
members of a single family, a sensitivity analysis including
only one randomly selected member per family was
performed. The association between the location of the
NOTCH3 PV and nWMHV was performed using stepwise
linear regression with forward selection. nWMHV was
entered as a dependent variable, and country, APOE genotype,
age, sex, hypertension, hypercholesterolaemia, diabetes and
smoking were entered as independent variables. Mutation
location was grouped into EGFr 1–6 and EGFr 7–34, and
EGFr group was included as an additional independent
variable. For all analyses, the ⍺ level (i.e. the significance
level) was set at 5%.
RESULTS
Mutations in NOTCH3 EGFr domains 1–6 are associated
with an earlier onset of stroke than PV in EGFr domains
7–34
First, we compared the age at onset of stroke in the 153 Dutch
CADASIL patients with an EGFr 1–6 PV with the 98 patients
with an EGFr 7–34 PV. At the time of the DNA test, patients
with an EGFr domain 1–6 PV were on average 8.2 years
younger than patients with an EGFr 7–34 PV (44.3 years
versus 52.5 years, P < 0.001, independent-samples t-test)
(Table 1), suggesting that patients with a PV in EGFr
domains 1–6 are diagnosed at a younger age. In the group of
patients with an EGFr 1–6 PV, 41.2% had experienced at least
one stroke, compared to 30.6% of patients with an EGFr 7–34
PV (P= 0.091, Chi-squared test). In time-to event-analysis,
median latencies until first stroke were age 55 for patients
with an EGFr 1–6 PV and age 67 for those with an EGFr 7–34
PV (P < 0.001, log-rank test) (Fig. 1a). After correction for sex
and cardiovascular risk factors, the location of the PV was the
highest predictive covariate for age at first stroke, with a
hazard ratio (HR) for EGFr 1–6 PV versus EGFr 7–34 PV of
2.63 (95% confidence interval (CI)= 1.61–4.31, P < 0.001,
Cox-regression analysis). There was no significant effect of
hypertension or smoking status (HR= 1.45, 95% CI=
0.90–2.30, P= 0.121; and HR= 1.74, 95% CI= 0.63–1.56,
P= 0.97, respectively). The effect of NOTCH3 PV position on
age at first stroke was not influenced by family of origin (i.e.,
when including only one individual per family, similar results
were found). Prevalence and age at onset of migraine with
aura did not differ between patients with an EGFr 1–6 PV and
patients with an EGFr 7–34 PV (35.6 versus 32.6%, P= 0.638,
Chi-squared test; and 30.6 versus 26.6 years, P= 0.24,
independent-samples t-test, respectively).
Correlation between NOTCH3 PV position and survival
Next, we compared survival rates between patients with a
NOTCH3 EGFr 1–6 PV and patients with an EGFr 7–34 PV.
At the end of 2017, 28 out of 153 Dutch patients with an EGFr
1–6 PV were deceased (18.3%), compared with 8 out of 98
patients with an EGFr 7–34 PV (8.2%) (P= 0.025, Chi-
squared test). The mean survival time was 68.5 years for
patients with an EGFr 1–6 PV, compared with 76.9 years for
Table 1 Characteristics of patients in the Dutch CADASIL
sample
EGFr 1–6 EGFr 7–34 P
value
n 153 98
Mean age at DNA test (years
(95% CI))
44.3
(42.3–46.3)
52.5
(50.2–54.8)
<0.001
Male/female (% male) 69/84
(45.1%)
42/56
(42.9%)
0.727
Smoking, yes/no (%) 69/75
(47.9%)
50/35
(58.8%)
0.110
9 unknown 13 unknown
Hypertension, yes/no (%) 30/114
(20.8%)
33/54
(37.9%)
0.005
12 unknown 11 unknown
Diabetes, yes/no (%) 11/134
(7.6%)
6/79 (7.1%) 0.883
8 unknown 13 unknown
EGFr Epidermal growth factor-like repeat
ARTICLE RUTTEN et al
678 Volume 21 | Number 3 | March 2019 | GENETICS in MEDICINE
patients with an EGFr 7–34 PV (P= 0.004, log-rank test)
(Fig. 1b). After correction for sex and cardiovascular risk
factors, the location of the PV was the highest predictive
covariate for survival (HR= 3.11, 95% CI= 1.16–8.34, P=
0.024, Cox-regression analysis).
Mutations in NOTCH3 EGFr domains 1–6 are associated
with a higher WMH volume than PV in EGFr domains 7–34
We previously found a correlation between NOTCH3 PV
position and brain MRI lesion load in a small cohort of Dutch
CADASIL patients.4 To validate these findings, here, we
analysed the relationship between the position of the
NOTCH3 PV and nWMHV on brain MRI in an independent
sample of 412 European CADASIL patients.7 At the time of
their MRI scan, patients with a PV in EGFr domains 1–6 were
younger than patients with a PV in EGFr domains 7–34 (48.8
versus 57.3 years, P < 0.001) (Table 2). Using stepwise
regression, we found a significant association between
PV location and nWMHV, where EGFr 1–6 PV are
associated with a higher nWMHV than EGFr 7–34 PV
(β=−0.144, t=−3.180, P= 0.002) (Fig. 2). There was a
small difference in the age-dependent increase in nWMHV
for individuals with an EGFr 1–6 PV versus individuals with
an EGFr 7–34 PV, but this difference did not reach statistical
significance (P= 0.132). Finally, we looked specifically at a
possible effect of PV in the ligand-binding domain (EGFr
10–11). Interestingly, despite the overall effect of a lower
nWMHV in the higher-numbered EGFr domains, we found
that the average nWMHV in the 14 individuals with an EGFr
10–11 PV was higher than the average nWMHV in the rest of
the sample (β=−0.122, t=−3.220, P= 0.001) (Figure S1).
EGFr domain 7–34 PV are much more prevalent in the
general population than EGFr domain 1–6 PV
Finally, we compared the location of EGFr cysteine-altering
NOTCH3 missense PV between a large population sample
(European individuals in gnomAD, n= 76,266) and the 463
patients included in the European CADASIL sample. In
gnomAD, there were 450 individuals with a cysteine-altering
NOTCH3 PV (Figure S2). This corresponds to a frequency of
3.2 per 1000 individuals, which is in line with our previous
findings in the ExAC database.4 Of the 450 individuals with a
NOTCH3 PV in gnomAD, 120 individuals were of European
descent. Only a small minority of these had a PV in EGFr
domains 1–6 (2.5%). In contrast, most of the patients in the
European CADASIL sample had a PV in EGFr domains 1–6
(71.1%) (Fig. 3). This shows that, although cysteine-altering
NOTCH3 PV are distributed along the 34 EGFr domains in
both CADASIL patients and the general population, in
diagnosed CADASIL patients the PV are predominantly
located in one of EGFr domains 1–6, whereas in the general
population the PV are predominantly located in one of EGFr
domains 7–34. This strongly suggests that EGFr 7–34
PV predispose to a much milder phenotype, which we
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Fig. 1 Mutations in NOTCH3 EGFr domains 1–6 are associated with
an earlier age of onset of stroke and lower life expectancy than PV
in EGFr domains 7–34. a, b, Kaplan–Meier plots showing the differences
in (a) age of onset of first stroke and (b) survival stratified according to
mutation position for patients with epidermal growth factor-like repeat
(EGFr) domain 1–6 PV versus those with EGFr domain 7–34 PV
Table 2 Characteristics of patients in the European CADASIL
sample
EGFr 1–6 EGFr 7–34 P
value
n 290 122
Mean age (years (95% CI)) 48.8
(47.5–50.1)
57.3
(55.3–59.4)
<0.001
Male/female (% male) 130/160
(44.8)
55/67 (45.1) 0.962
Smoking, yes/no (%) 84/206 (29.0) 18/104 (14.8) 0.002
Pack years 5.7 (4.2–7.2) 13.0
(−0.4–26.3)
0.11
Hypercholesterolaemia, yes/
no (%)
129/161
(44.5)
63/59 (51.6) 0.184
Hypertension, yes/no (%) 45/245 (15.5) 38/84 (31.1) <0.001
Diabetes, yes/no (%) 6/284 (2.1) 3/119 (2.5) 0.728
EGFr Epidermal growth factor-like repeat
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also show to be the case even within diagnosed CADASIL
patients.
DISCUSSION
This study shows that the PV position along the 34 EGFr
domains of the NOTCH3 protein plays an important role in
the NOTCH3 disease spectrum, with EGFr domain 1–6 PV
predisposing to ‘classical’ CADASIL, while EGFr domain
7–34 PV predispose to a milder phenotype. We found that
CADASIL patients with an EGFr domain 1–6 PV had a
12-year-earlier age at onset of stroke, lower survival time and
greater brain MRI lesion load than patients with an EGFr
domain 7–34 PV. We also found that the EGFr PV position is
the strongest predictor of CADASIL disease severity after age.
This PV position effect would probably be even stronger if the
phenotype of individuals in the population were included in a
genotype–phenotype correlation study, as the vast majority of
individuals with a cysteine-altering NOTCH3 PV in the
general population have an EGFr domain 7–34 PV.
We have extrapolated that of all individuals with an EGFr
cysteine-altering NOTCH3 PV, only approximately 1% are
diagnosed with CADASIL (i.e., most individuals with these
PV reside in the general population, rather than in the
diagnosed CADASIL population). This is a striking finding as,
to date, these distinctive EGFr cysteine-altering NOTCH3 PV
have been considered to be specific for CADASIL and
confirmative of a diagnosis. We speculate that NOTCH3 EGFr
7–34 PV in a population sample could well be associated with
attenuated CADASIL or a late-onset small-vessel disease
phenotype, which may be largely indistinguishable from what
is currently considered to be a ‘normal’ cerebrovascular ageing
process (i.e., an elderly onset of mild cognitive deficits,
ischaemic events and some degree of WMHs on MRI). This
hypothesis is supported by the increasing number of
CADASIL patients who are diagnosed above 65 years of age,
showing that even within known CADASIL families, cysteine-
altering NOTCH3 PV can be associated with a relatively mild,
later-onset phenotype.4,15,16 From the population perspective,
it is therefore possible that cysteine-altering NOTCH3 PV in
higher EGFr domains are a hitherto overlooked risk factor for
cerebral small-vessel disease in the (elderly) population.
Whether PV in higher-numbered EGFr domains can be
non-penetrant remains to be determined.
Cardiovascular and other genetic risk factors have pre-
viously been described to contribute to CADASIL disease
severity.5 Possibly, EGFr 7–34 PV require a higher additional
(vascular) risk-factor profile before causing CADASIL or a
small-vessel disease phenotype, whereas an EGFr 1–6 PV
alone almost always predisposes to a ‘classical’ CADASIL
phenotype. Indeed, in both the European and Dutch
CADASIL patients, the prevalence of hypertension was higher
in patients with an EGFr 7–34 PV, even after correcting for
age. NOTCH3 PV position and traditional vascular risk
factors are probably only the first in a list of players
determining NOTCH3 disease severity, considering the fact
that individuals with the same PV, or even within the same
pedigree, can show variability in disease onset and progres-
sion. In our study, we found that disease severity was more
strongly determined by NOTCH3 PV position than by
hypertension or smoking. Taken together, it is important to
include PV position in future NOTCH3 disease prediction
models, which need to be developed to help predict disease
severity in newly diagnosed CADASIL patients, and especially
in individuals in whom a cysteine-altering NOTCH3 PV is
revealed as a chance finding through exome or genome
sequencing.
We can only speculate as to the mechanisms underlying the
NOTCH3 PV position effect, which may lie anywhere from
protein expression and processing to protein interactions and
differences in mutant NOTCH3 aggregation properties.
Interestingly, despite an overall effect of higher-numbered
EGFr domains being associated with a milder phenotype,
we found that PV in EGFr domains 10 and 11, which
comprise the ligand-binding domain and lead to reduced
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Fig. 2 Mutations in NOTCH3 EGFr domains 1–6 are associated with
a higher nWMHV than mutations in EGFr domains 7–34 . Scatterplot
showing the correlation between normalized white matter hyperintensity
volume (nWMHV) and age, stratified according to epidermal growth factor-
like repeat (EGFr) group. Diagnosed CADASIL patients with a mutation in
one of EGFr domains 1–6 have a higher nWMHV than patients with a
mutation in one of EGFr domains 7–34
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Fig. 3 Location of NOTCH3 mutations between diagnosed CADASIL
patients and individuals in the gnomAD database. Pie charts display-
ing the differences in the number of mutations located in EGFr domains 1–6
versus 7–34, between European CADASIL patients and European indivi-
duals with a NOTCH3 mutation in gnomAD
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NOTCH3 signalling,21–24 are associated with a higher WMH
lesion load when compared with all other EGFr domains. We
could not assess the association of EGFr 10–11 PV with age at
first stroke or survival because the number of patients with a
PV in the ligand-binding domain in the Dutch CADASIL
sample was too low for reliable analysis. Previous studies have
reported contradictory findings regarding patients with a
ligand-binding domain PV; both a milder and more severe
phenotype have been described.22,25 Larger studies including
more phenotypic information are needed to determine
whether there is an additional effect of specific EGFr domains,
including the ligand-binding domain.
In conclusion, we show that CADASIL patients with
an EGFr domain 1–6 PV have a more severe CADASIL
phenotype than patients with an EGFr domain 7–34 PV,
where EGFr 7–34 PV are by far the most common in
the general population. These findings strongly suggest that
the presence of an EGFr 1–6 PV alone predisposes to the
classical, more severe CADASIL phenotype, whereas the
EGFr 7–34 disease spectrum is much broader, ranging
from an attenuated CADASIL phenotype to (possibly)
non-penetrance. This completely transforms the
CADASIL–NOTCH3 disease paradigm, as patients who are
currently diagnosed with CADASIL are merely the tip of
the iceberg of individuals with a NOTCH3 PV, and probably
represent only the severe end of the NOTCH3 disease
spectrum. Identifying these patients at risk for early-onset,
severe disease will facilitate biomarker and clinical endpoint
development, as well as appropriate patient selection and
inclusion in future clinical trials.
The role of NOTCH3 PV in the general population in
relation to cerebral small-vessel disease will probably be
clarified in the near future as large study cohorts become
available, including not only exome- and genome-sequencing
data, but also MRI and other clinical phenotyping. Discover-
ing which factors protect the majority of individuals
harbouring such PV from developing a classical CADASIL
phenotype will probably lead to new insights for disease
prevention, and possibly also to the identification of targets
for therapeutic intervention.
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